Search results
Author(s):
Gregory Marcus
Added:
2 years ago
Dr Gregory Marcus (University of California, San Francisco, CA, US) shares the results from the HOLIDAY Monitors Trial. This study assessed how ethanol may trigger episodes of atrial fibrillation (AF).
Questions
What is the HOLIDAY Monitors Trial and what does it aim to address?
What was the study design, patient population and endpoints?
What are the main findings to date?
What conclusions can…
View more
Author(s):
Mikhail Kosiborod
Added:
2 years ago
In this interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO, US)discusses the outcomes of the Dare-19 Trial, which aimed to study the effects of dapagliflozin in COVID-19 patients with risk factors for complications.
Questions:
What prompted you to conduct the DARE-19 Trial?
What was the design, patient population and endpoints?
What are your key findings?…
View more
Author(s):
Jose L Merino
Added:
1 year ago
In this late-breaking interview filmed at EHRA 2022, Dr José Merino(Hospital Universitario La Paz, Madrid, Spain) discusses the findings of the POWER-FAST III trial, a study that aimed to compare atrial fibrillation ablation strategies of conventional radiofrequency ablation and high power radiofrequency ablation. Results suggest that PVA was achieved in both cohorts, with no significant…
View more
Author(s):
Jason G Andrade
Added:
1 year ago
In this short late-breaking interview, Dr Jason Andrade (Vancouver General / Montreal Heart Institute, Montreal, CA) joins us at EHRA 2022 to outline the findings of a meta-analysis of EAST-AFNET 4. The main outcomes suggest that early rhythm control therapy is beneficial for AF patients, reducing their cardiovascular outcomes.
Discussion points:
Reasoning behind this meta-analysis
Study…
View more
Author(s):
Federico M Asch
Added:
3 years ago
Dr Federico M Asch (MedStar Health Research Institute, Georgetown University, Washington DC, WA, US) discusses the latest findings from the Global EXPAND Study. Their research looked into mitral valve leaflet events with MitraClip (NTR/XTR).
Questions:
1. Can you briefly remind us what the EXPAND registry is and what it assesses?
2. What research have you conducted on leaflet adverse…
View more
Foreword
Author(s):
Carlo Di Mario
Added:
3 years ago
Article
Author(s):
Joo-Yong Hahn
Added:
1 year ago
ACC.23/WCC - Principal investigator, Dr Joo-Yong Hahn (Samsung Medical Center, KR) joins us to discuss the findings of the RENOVATE-COMPLEX-PCI late-breaking trial (Samsung Medical Center). The investigators compared clinical outcomes between intravascular imaging guided (IVUS) versus angiography guided (OCT) percutaneous coronary intervention (PCI) in 1639 patients with complex lesions …
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more
Author(s):
Jose L Merino
,
José López-Sendón
Added:
3 years ago
Atrial fibrillation (AF) is the most frequent sustained arrhythmia. The estimation is that five million people suffer the disease in Europe,1 although this number may be even higher because many AF episodes are silent but still associated with a risk of complications.2–4 AF prevalence is increasing in developed countries in part due to the progressive increase in the mean age of the western…
View more
Author(s):
Peter M Nilsson
Added:
3 years ago
Some cardiovascular (CV) risk-prone patients are easy to recognise, for example following manifestations of cardiovascular disease (CVD), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) interventions, and they deserve appropriate risk-factor control for secondary prevention, including blood pressure (BP) lowering. However, many other at-risk patients…
View more